# TPST-2003

Source: https://onco.cc/drugs/tpst-2003/  
OnCo record `tpst-2003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TPST-2003 is a CAR-T cell treatment, made from a patient's own immune cells, from Tempest Therapeutics. It targets two markers and is being tested in multiple myeloma that has come back.

## Summary

TPST-2003 is an autologous CD19 and BCMA CAR-T therapy whose rights Tempest Therapeutics acquired in February 2026. Tempest describes it as in clinical development for relapsed or refractory multiple myeloma and for POEMS syndrome, a rare plasma cell disorder; the filing does not state the phase.

## Fields

- Kind: Treatment
- Last checked: 2026-11-04
- Tags: pipeline
- Code: TPST-2003
- Modality: Autologous CAR-T (dual CD19 and BCMA)
- Mechanism: An autologous T cell therapy carrying a dual-targeting CD19 and BCMA chimeric antigen receptor, as described by Tempest Therapeutics.

## Sources

- SEC: Tempest Therapeutics Form S-1, August 2026: https://www.sec.gov/Archives/edgar/data/1544227/000119312526361240/d181522ds1.htm

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- companies: [Tempest Therapeutics](https://onco.cc/companies/tempest-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/tpst-2003.json